Welcome to the online version of our Annual Report Newsletter

We know you will find the articles of interest to you

ANNUAL REPORT 2017

President’s Message Monica H Bellizzi TIME-LY—“Occurring at a favorable or useful time, Op-portune, apropriate, expedient”

As you have birthdays, there is a realization that time and years are adding up. It is in your best interest to spend the moments in a TIME-LY manner. To laugh, hug, smile more. To look at how you spend your time.

.When is the right time?????That is a question asked by Dr. Sales. Time and being timely becomes an im-portant part of eye care. Along with finding the knowledge needed, a Surgeon, the decision is go forward is difficult to make and takes much courage. Read this article and see where you are in the time continuum.

Twelve years’ time of work is published. Dr. Afshari ’s genetic study involving many of Fuchs’ Friends who literal-ly gave their blood and saliva and have made their contri-bution to scientific study. Thank you, for all who waited in line at the Raleigh symposium, those who mailed in their tests, and had the patience to wait for the results. Read Dr. Afshari’s note and thank you. Websites are listed to access the published paper.

It is time-ly for me to thank you for all your support, wheth-er it was in dollars, volunteer hours, thank you notes, sur-vey responses, however you connected with us. We love hearing from you. You all “Rock”.

New Genetic Loci Found for Fuchs’ Dystrophy

Great news from Dr. Afshari’s Genetic Study! The link to the article in Nature Communications and the

News release links from University of California San Diego as well as National Institutes of Health/National Eye Institute are below. A very special thanks goes to you and to all of the Fuchs Friends for your support over the years. This publication is cul-mination of over 12 years of genetics study of Fuchs and would have not been possible without gracious participation of so many individuals with Fuchs and also control individuals. We are very thankful to every single person who participated in the study.

Nature Communications Article Link http://www.nature.com/articles/ncomms14898 NIH Link https://www.nei.nih.gov/content/nih-funded-team-

identifies-genetic-underpinnings-fuchs-dystrophy%20%3chttps:/www.nei.nih.gov/content/nih-funded-team-identifies-genetic-underpinnings-fuchs-dystrophy%3e

UCSD Link https://health.ucsd.edu/news/releases/Pages/2017-03-30-new-genetic-links-underlying-progressive-eye-disease.aspx

Natalie Afshari MD, Stuart I. Brown MD Chair in Ophthalmology in Memory of Donald P.Shiley Professor of Ophthalmology Chief of Cornea & Refractive Surgery Vice Chair of Education Shiley Eye Institute University of California, San Diego

866-807-8965

6066 McAbee Road San Jose, CA 95120

newsletter@cornealdystrophyfoundation.org

newsletter@cornealdystrophyfoundation.org

484,121 People searched for information on The Corneal

Dystrophy Foundation Website (Aug 2009-Dec

382,456 First time visitors to the website

9,400 New members joined Fuchs’ Friends, the online

Thank you, to those Fuchs Friends members who com-

pleted our online survey recently. We will soon release

results to the group

When is the right time to under-

go a partial (DMEK) transplant

for Fuchs’ Dystrophy?

Fuchs’ (fooks) endothelial dystrophy is a problem that affects the corneal endothelium’s smoothness and its pumping function.

Endothelial cells in individuals with Fuchs’ are intermixed with abnormal cobblestone-like bumps called guttata, which disrupt the smooth inner surface of the cornea. The formation of an increasing number of guttata in the center of the cornea, where they have the greatest effect on vision, is a hallmark of Fuchs’. A moderate to severe concentration of guttata can blur vision, reduce contrast, and cause glare symptoms by causing light to scatter in a manner that is similar to, but not as pronounced as, the frosted glass etched into shower doors for privacy. Blurry vi-sion and a reduction in the quality of your vision caused by corneal guttata make up the first phase of disease progression of Fuchs’ – well before you devel-op corneal swelling.

Fuchs’ patients eventually lose so many endothelial cells that there is not enough pumping function to op-pose the cornea’s natural tendency to absorb fluid. The result is swelling of the cornea, which causes your vision to become blurrier. In its early stages, corneal swelling blurs your vision in the morning and not as much in the evening, but eventually the swelling wors-ens to the point that your vision remains blurry throughout the day. Blurrier vision caused by corneal swelling makes up the second phase of disease pro-gression of Fuchs’.

Longstanding corneal swelling causes the superfi-cial layers of the cornea to become permanently scarred, and if severe, it can also cause painful blister-ing. Scarring further blurs your vision, sometimes per-manently. Scarring and pain make up the final phase of disease progression of Fuchs’.

Fuchs’ dystrophy can be a distressing diagnosis, but, thankfully, it is not a medical emergency. Most individuals with Fuchs’ are unaware that they have the condition until they are about 40-50 years of age be-cause the disease does not typically interfere with visu-al function in the first few decades of life.

Most patients with symptomatic Fuchs’ first notice that colors look washed-out and that bright lights cause them to experience glare. Patients with these symp-toms typically have early stages of the disease (i.e. guttata with or without early corneal swelling). Recog-nizing these symptoms and seeking specialized care during the early stages of Fuchs’ helps ensure that you receive appropriate treatment before your corneas have become permanently damaged from more ad-vanced stages of the disease (i.e., scarring from longstanding corneal swelling).

Corneal scarring is the one factor that imparts a degree of urgency to deciding when to have a DMEK corneal transplant. In general, corneal scarring limits vision, but it can sometimes improve after surgery. Undergoing DMEK surgery before your corneas have significantly scarred gives you the best chance of hav-ing good vision after the procedure.

The potential for DMEK surgery to provide rapid and complete visual rehabilitation has enabled ophthal-mologists to offer surgical treatment at earlier stages of Fuchs’ compared to when full-thickness corneal trans-plant surgery was the standard-of-care for endothelial disease. In the age of DMEK, it is no longer the norm to wait until you have developed severe corneal swell-ing or scarring before having surgery. Earlier stages of Fuchs’, if visually significant, are reason enough to pro-ceed with DMEK surgery. But, as you might expect, “visually significant” can mean very different things to different individuals based on what their daily activities involve and how well they are coping with a reduction in visual function.

Not renewing your driver’s license because you failed the vision test is a stark example of when most patients would begin considering surgical intervention for Fuchs’. But in my experience, the majority of pa-tients with Fuchs’ (with or without cataracts) fall into a much more nuanced gray zone.

For many patients with Fuchs’, life has become more difficult or less enjoyable because of their dis-ease, but they have managed to adapt to and/or ac-cept whatever limitations Fuchs’ has imposed on them. For example, a patient with moderate guttata and mild swelling might avoid driving at night because she feels uneasy about it, but not to the point of cancelling ap-pointments. The same patient might have difficulty

(Continued on page 3)

ANNUAL REPORT 2017

spotting the golf ball, but still manage to play the occa-sional round if she’s with friends.

For the vast majority of patients in the “gray zone,” odds are good that a DMEK corneal transplant per-formed by an experienced surgeon will improve or re-solve their symptoms. But the decision to have DMEK surgery is nevertheless emotionally daunting because the potential improvements in vision and quality of life provided by the procedure as well as its risks are rela-tively abstract. By comparison, whatever compromises have been made to one’s life because of Fuchs’ are concrete and, despite not being ideal, are at least a known quantity.

Helping patients to vicariously experience what DMEK surgery and recovery are like and, more im-portantly, how life can improve afterwards is an invalu-able contribution of the Fuchs’ Friends online forum to patients with Fuchs’. Fuchs’ Friends helps bridge the gap of patients’ uncertainty, which is a tremendous benefit for both surgeons and patients alike.

In summary, deferring a corneal transplant until vis-ual symptoms affect your daily activities remains a good guidepost for when to consider surgery, but you don’t have to wait until you are incapacitated to consid-er having a DMEK corneal transplant. You should con-sider having DMEK surgery once your visual symp-toms significantly affect your quality of life – at whatev-er stage of Fuchs’ that might be. When weighing whether to have DMEK surgery, remember: your sur-geon can tell you how the disease is affecting your cor-neas, but only you know how it is affecting your happi-ness, which can be just as important. For the most part, the timing is up to you, but you should have sur-gery before your corneas develop significant scarring to maximize your chances of enjoying good vision after a DMEK corneal transplant.

When is the right time to undergo cataract surgery with Fuchs’ Dystrophy?

If you have Fuchs’ dystrophy, your decision to have cataract surgery is complicated and should be dis-

cussed with a doctor who specializes in your condition. Your decision to have cataract surgery will likely not just be a decision about cataracts, but also a decision about Fuchs’, which can usher in the potential to fully rehabilitate your vision with a DMEK corneal trans-plant.

If your disease is not advanced, cataract surgery alone can sometimes improve the visual symptoms caused by Fuchs’ without eliminating them, but it can also make them worse by causing irreversible damage to your endothelial cells. Special precautions should be taken during cataract surgery in individuals with Fuchs’, but if the damage caused by the surgery is still too great, a subsequent DMEK corneal transplant may be required.

It is usually not possible for individuals with Fuchs’ to altogether avoid cataract surgery in their lifetime, even if a DMEK corneal transplant is performed with-out preceding cataract surgery. Many patients over the age of 50 who have a DMEK corneal transplant prior to having cataract surgery will need cataract sur-gery anyway within a few years. Having cataract sur-gery after DMEK surgery, although possible, is also not the preferred order of operations for preserving the health of transplanted endothelial cells.

The ideal approach is either to combine cataract surgery with DMEK corneal transplant surgery in one procedure or to plan for a two-stage procedure in which the cataract surgery is performed first and the DMEK surgery is performed second, a few days or weeks afterwards. Most patients and surgeons prefer one of these options because addressing both the cat-aract and Fuchs’ provides the best possible chance of restoring clear, vivid vision.

(Continued from page 2)

Christopher S. Sales, MD, MPH is an Assistant Professor of Ophthalmology at Weill Cornell Medical College in New York, NY, and an Assistant Medical Director at the Lions VisionGift Eye Bank in Port-land, OR. He completed residency training at Stan-ford University in Palo Alto, CA, and fellowship train-ing with Drs. Mark Terry and Mike Straiko at the Devers Eye Institute in Portland, OR.

Become a Donor! The Corneal Dystrophy Foundation supports education

and advocacy related to sight threatening corneal dystrophies. We are financed

by donations from the public. thank you for your support!

https://www.cornealdystrophyfoundation.org

Order

Free Literature

https://www.cornealdystrophyfoundation.org/catalog

Instructional DVD Sets (Donation Required)

https://www.cornealdystrophyfoundation.org/catalog/dvds

Innovators $1000 & Over

Deloris Axelrod Monica H Bellizzi Robert J Black Thrivent Choice Thrivent Financial Louise Grobli Martin Razoo

Patrons $100 Up To $999

Almaden Super Lions Don Augenstein Ravi K Babbellapati Daniel Ballard R Bellizzi Benevity Community Im-pact Fund Sandra Blumenfeld Winifred & Glenn Bowen Anthony Braubach Lana Bridge Carol M Budge David Calloway Fiona Campbell Leonard A Carlson Susan Carson Anne Chaffee Lynn Chmura Edward Colburn Emma M Collins Boyd Combs Johnelle Cooper Carolyn Corliss Constance Cunningham Barbara Day Jerry Downing Ron Flaum Janet Rice Forsman Alan Frisoni S Hewitt Fulton Iii Pamela Gibson Michal Hansen Mary Harris Joann Hawley Ellen Heitzhaus Elizabeth Hilferty Justgivedonation Carolyn Ketchel Jody Klotzle Mary A Koerner Diane Krug James Lamson Shirley Landen Bruce Lanfried William Langdon Linda Langford

Shelby Lee Vicki P Lee Sandra Lewis Sandra S. London Mary Agnes Luby Dorothy Lurie Glenna L. Maguire Rita Marokko Stephen Meyers Nancy T Miller Jane Minnick Maureen C Murray Matthew Oliva Md Christine Place Sue B Plaster Mary Pollock Lydia Rabinowitz Maree Rogers Ursula Rolfe Doris Sadovy Larry Schrimp Carol Schwinger Kathy Sena Elaine Shaw Amazon Smile William C. Smith Philippa Strahm Robert S Suda Jean Switzer Tobi Margaret J Velardo Teresa Verola Wendy Weiber Marilyn Weinberg Allissa M Wheeler Diane Williams Linda Winningham Carol Wooding Donna Woods

Supporters Up To $99

Kathryn Aceto Mustafa Adra Barbara Allen Amazon.Com Anna Androczi Frank Ayers Sheila Barton Samuel Bell Robert C Bellizzi Lee Perry Bender Ruth E. Bernitsky Nancy Bizek Dorothea Bowen Garrett Bragalone John Brasko Carol Brown

Mike Brown Dennis Campanaro Carolyn Caulkins Barbara Cevasco Sabine M Chrisman Robert Clark Ruth Clark Kathleen Clements Debra Coley Marilyn Cooney Glyde Corporation Linda Culpepper James Cummings Janet D'arcangelo Jack Davis Paul Di Zefalo George Dilgard Judy Dillie Mary Sue Dillon Candace Dittenber Ed Dobrowolski Donna Downs Mark Drury Carol Duffy Terrie Ellis Escripincome Linda Eyer Mary FIORE G Andrew Franz George Frayne Arvind Gangal Ron Gauerke Dallas Giddens David Glasser Barbara Gorvad Dennis Greiner Wanda Grosch Rachelle S Guthrie Phyllis Halgas Beth Harris Patricia A Harris Dorothy E Hathaway Kristin Hayek Robert Heidlage Kim Higgins Donna Hill Judy Holder Dorothy Hullin Arlette Hunnakko Igive Randy Infusino Marie Jackson Sondra Jaffe Jan James Judith James Gerri Jenkins Linda Jensen

Janet J Johnsen Sherry Kaderli Dona Kenline Joann Kentgen Donna Kerns Walter Kilgore Florence Klancer Vicki Knight Lorraine M Kogler Moira Kussin Susan Lees Donna Leistner Diane Lesnick Alice Lewinski Cynthia Lewis Pamela Livermore Dorothy A Locy Kurt J Loeswick Gregory Lynn Deborah Macneill Dianne Maddaus Dolores Malick Marjorie Marlowe Patricia Martin Mona Martinka Janet Masey David Matz S Maximous Lauren Mcinally Helen M Meyer Mitchell Family Trust Beverly O Monroe Mary Lou Mudge Susan Murphy Francine K Neall Roselyn Nicewarner Maria M Nicholson Susan Nitkin Karen Norris Robert H Olsen Nancy Pasulka Gudrun E Patrick Silvina Pedernera Ann Possinger Barbara Quart Wendy Regas Janis Remy Pamela Ribon Monika Ries Eleanor Rioux Jennifer Rizzo Mike Robbins Claudia Rodriguez Nancy Rodriguez Rosa Rohr Susan Rood Carol Rosenberg

Edward Rudder Barbara Russo Gershon Sabol Gail Sailors Suzy Saunders Carol Savage Mary Schenzer Margarete Schranz Joyce Schreiber Norma Service Deborah Silverman Lavina Skinner Bradley M Smith Carole Smith Eva Mae Spielman Martha Steger Jackie Stewart Cecil Stokes Gatana Stoner John E Sutphin Md Frederick Szydlik Gail Tait George D Thomas Linda Thompson Daniel Tufford Yvette Van Hennekeler Evelyn Van Zanten Ann Wagner Jeanne Wainer Terence Walker Sandra Wendt Maryan W White James Whittemore Jack Williams Mildred Williams Miriam L Zimmerman

Dear CDF,

Thank you for the

wonderful service you

all provide.

Sincerely,

Merry N.

~ ~ ~ ~ ~ ~

Thank you so much

for sharing your

story.

Gayle

Contributors during 2016

We wish to thank our donors. With their support, resources were made available to help those with Corneal Dystrophies.